FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Nonprescription Panel Renewed for 2 Years

[ Price : $8.95]

Federal Register notice: FDA renews the Nonprescription Drugs Advisory Committee for an additional two years.

Former BD Exec Petitions FDA on Mesh Products

[ Price : $8.95]

Former Becton Dickinson medical director Hooman Noorchashm petitions FDA to warn patients about the unknown and inadequately studi...

ODAC Looking at Long Delays in 2 Acrotech Trials

[ Price : $8.95]

FDA asks the Oncologic Drugs Advisory Committee whether Acrotech Biopharmas plan to complete a confirmatory trial for two cancer d...

Cardinal Health Recalls Infusion Pump Syringes

[ Price : $8.95]

Cardinal Health recalls its latest version (6/2023) of its Monoject syringes branded as Cardinal Health Monoject syringes because ...

Comments on Cell & Gene Comparability Guide

[ Price : $8.95]

Four stakeholders comment on an FDA draft guidance on comparability of human cell and gene therapy products and suggest improvemen...

Imfinzi Phase 3 Trial Fails

[ Price : $8.95]

AstraZeneca says its Imfinzi failed to achieve statistical significance in the PACIFIC-2 trial in some non-small cell lung cancer ...

FDA Lawyer Nguyen Moves to Cooley

[ Price : $8.95]

Law firm Cooley adds 14-year FDA lawyer Son Nguyen to the firms Washington, DC office.

Congress Should Do More on Drug Shortages: Analysis

[ Price : $8.95]

Manhattan Institute senior fellow and former FDAer Randall Lutter says there are many things Congress should be doing to alleviate...

Improve Post-Market Evidence Generation: Report

[ Price : $8.95]

The Reagan-Udall Foundation recommends steps to be taken by FDA and other stakeholders to improve evidence generation in postmarke...

Republicans Threaten Subpoena on FDA Research

[ Price : $8.95]

House Energy and Commerce Committee Republicans threaten FDA with a subpoena if it continues to delay submitting documents on what...